Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara Murphy

Showing results (101-110 of 167) with videos related to

Pageof 17
Sort By:
Cancer|July 19, 2011
Phase 2 trial of oxaliplatin and pemetrexed as an induction regimen in locally advanced head and neck cancerJill Gilbert, Barbara Murphy, Mary S Dietrich, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 20, 2008
Inhibition of the alloimmune response through the generation of regulatory T cells by a MHC class II-derived peptideWeiping Zang, Marvin Lin, Safa Kalache, et al.
Seminars in Radiation Oncology|August 7, 2003
CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatmentAndy Trotti, A Dimitrios Colevas, Ann Setser, et al.
Archives of Otolaryngology--Head & Neck Surgery|April 20, 2005
Phase 2 bioadjuvant study of interferon alfa-2a, isotretinoin, and vitamin E in locally advanced squamous cell carcinoma of the head and neck: long-term follow-upJose A Seixas-Silva, Thomas Richards, Fadlo R Khuri, et al.
The Journal of Pediatrics|December 3, 2014
Referral of very low birth weight infants to high-risk follow-up at neonatal intensive care unit discharge varies widely across CaliforniaSusan R Hintz, Jeffrey B Gould, Mihoko V Bennett, et al.
Trials|November 8, 2022
Conducting a supportive oncology clinical trial during the COVID-19 pandemic: challenges and strategiesJie Deng, John N Lukens, Joy C Cohn, et al.
Cancer|March 23, 2007
Longitudinal evaluation of the oral mucositis weekly questionnaire-head and neck cancer, a patient-reported outcomes questionnaireJoel B Epstein, Jennifer L Beaumont, Clement K Gwede, et al.
Kidney360|April 4, 2022
Initial Validation of a Machine Learning-Derived Prognostic Test (KidneyIntelX) Integrating Biomarkers and Electronic Health Record Data To Predict Longitudinal Kidney OutcomesKinsuk Chauhan, Girish N Nadkarni, Fergus Fleming, et al.
Oral Oncology|August 18, 2018
Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neckJared Weiss, Jill Gilbert, Allison Mary Deal, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 14, 2008
Addition of plasmapheresis decreases the incidence of acute antibody-mediated rejection in sensitized patients with strong donor-specific antibodiesEnver Akalin, Rajani Dinavahi, Rex Friedlander, et al.
Pageof 17

Showing results (101-110 of 167) with videos related to

Sort By:
Pageof 17
Cancer|July 19, 2011
Phase 2 trial of oxaliplatin and pemetrexed as an induction regimen in locally advanced head and neck cancerJill Gilbert, Barbara Murphy, Mary S Dietrich, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 20, 2008
Inhibition of the alloimmune response through the generation of regulatory T cells by a MHC class II-derived peptideWeiping Zang, Marvin Lin, Safa Kalache, et al.
Seminars in Radiation Oncology|August 7, 2003
CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatmentAndy Trotti, A Dimitrios Colevas, Ann Setser, et al.
Archives of Otolaryngology--Head & Neck Surgery|April 20, 2005
Phase 2 bioadjuvant study of interferon alfa-2a, isotretinoin, and vitamin E in locally advanced squamous cell carcinoma of the head and neck: long-term follow-upJose A Seixas-Silva, Thomas Richards, Fadlo R Khuri, et al.
The Journal of Pediatrics|December 3, 2014
Referral of very low birth weight infants to high-risk follow-up at neonatal intensive care unit discharge varies widely across CaliforniaSusan R Hintz, Jeffrey B Gould, Mihoko V Bennett, et al.
Trials|November 8, 2022
Conducting a supportive oncology clinical trial during the COVID-19 pandemic: challenges and strategiesJie Deng, John N Lukens, Joy C Cohn, et al.
Cancer|March 23, 2007
Longitudinal evaluation of the oral mucositis weekly questionnaire-head and neck cancer, a patient-reported outcomes questionnaireJoel B Epstein, Jennifer L Beaumont, Clement K Gwede, et al.
Kidney360|April 4, 2022
Initial Validation of a Machine Learning-Derived Prognostic Test (KidneyIntelX) Integrating Biomarkers and Electronic Health Record Data To Predict Longitudinal Kidney OutcomesKinsuk Chauhan, Girish N Nadkarni, Fergus Fleming, et al.
Oral Oncology|August 18, 2018
Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neckJared Weiss, Jill Gilbert, Allison Mary Deal, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 14, 2008
Addition of plasmapheresis decreases the incidence of acute antibody-mediated rejection in sensitized patients with strong donor-specific antibodiesEnver Akalin, Rajani Dinavahi, Rex Friedlander, et al.
Pageof 17